Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Harigaya, Yoriko ^a,e   Ngo, Dung ^a   Lesse, Alan J ^b   Huang, Vanthida ^c   Tsuji, Brian T ^a,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c MERCER UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DELTA HEMOLYSIN; HEMOLYSIN; UNCLASSIFIED DRUG; VANCOMYCIN; AGR PROTEIN, STAPHYLOCOCCUS AUREUS; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; TRANSACTIVATOR PROTEIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; BROTH DILUTION; COLONY FORMING UNIT; CONTROLLED STUDY; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PREVALENCE; REGULATOR GENE; RELIABILITY; BACTEREMIA; BACTERIAL COUNT; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRANS-ACTIVATORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 80054855034     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-287     Document Type: Article

References (17)

1. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004, 10:855-857.
2. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002, 56:657-675. 10.1146/annurev.micro.56.012302.160806, 12142482.
3. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009, 199:619-624. 10.1086/596629, 19199552.
4. Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007, 30:398-408. 10.1016/j.ijantimicag.2007.07.011, 17888634.
5. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003, 47:3040-3045. 10.1128/AAC.47.10.3040-3045.2003, 201119, 14506006.
6. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997, 350:1670-1673. 10.1016/S0140-6736(97)07324-8, 9400512.
7. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001, 47:399-403. 10.1093/jac/47.4.399, 11266410.
8. Voss A, Mouton JW, van Elzakker EP, Hendrix RG, Goessens W, Kluytmans JA, Krabbe PF, de Neeling HJ, Sloos JH, Oztoprak N, et al. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob 2007, 6:9. 10.1186/1476-0711-6-9, 2034580, 17892555.
9. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007, 45:329-332. 10.1128/JCM.01508-06, 1829006, 17108069.
10. Yusof A, Engelhardt A, Karlsson A, Bylund L, Vidh P, Mills K, Wootton M, Walsh TR. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol 2008, 46:3042-3047. 10.1128/JCM.00265-08, 2546754, 18596146.
11. Howden BP, Smith DJ, Mansell A, Johnson PD, Ward PB, Stinear TP, Davies JK. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol 2008, 8:39. 10.1186/1471-2180-8-39, 2289824, 18304359.
12. Wootton M, Avison MB, Bennett PM, Howe RA, MacGowan AP, Walsh TR. Genetic analysis of 17 genes in Staphylococcus aureus with reduced susceptibility to vancomycin (VISA) and heteroVISA. J Antimicrob Chemother 2004, 53:406-407. 10.1093/jac/dkh086, 14729744.
13. Sakoulas G, Eliopoulos GM, Moellering RC, Wennersten C, Venkataraman L, Novick RP, Gold HS. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002, 46:1492-1502. 10.1128/AAC.46.5.1492-1502.2002, 127153, 11959587.
14. . CLSI, Institute CaLS Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S15. Book Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S15 2005, City: CLSI, (Editor ed.^eds.), CLSI, Institute CaLS.
15. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. Journal of clinical microbiology 2001, 39:2439-2444. 10.1128/JCM.39.7.2439-2444.2001, 88167, 11427551.
16. Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007, 45:1511-1514. 10.1128/JCM.01262-06, 1865872, 17344363.
17. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period. J Clin Microbiol 2006, 44:3883-3886. 10.1128/JCM.01388-06, 1698298, 16957043.